Effect of Incubation Time on Zone Size of Antimicrobials by Disk Diffusion Method for Pseudomonas Aeruginosa
Article Sidebar
Main Article Content
Abstract
Background: Pseudomonas aeruginosa is a prominent pathogen in healthcare settings, notorious for its rapid development of resistance to multiple antimicrobial agents. Effective susceptibility testing is critical for managing infections caused by this bacterium. This study investigates the impact of varying incubation times on the efficacy of the disk diffusion method.
Objective: To evaluate the influence of incubation time on the zone sizes of antimicrobials against Pseudomonas aeruginosa using the disk diffusion method in a tertiary care setting.
Methods: Conducted at the Microbiology Department of Combined Military Hospital, Lahore, from October 2022 to March 2023, this descriptive study included 71 clinical isolates of Pseudomonas aeruginosa. Samples were inoculated on Mueller Hinton Agar and incubated at 35°C ±2°C for 6, 10, and 24 hours. Antimicrobial susceptibility was tested using a panel of clinically relevant antibiotics in triplicate, with zone sizes interpreted according to Clinical and Laboratory Standards Institute guidelines.
Results: Among the isolates, 59.15% were from males and 40.85% from females. The most affected age group was 15-60 years, comprising 59.52% of cases. Antimicrobial response varied with incubation times: Ceftazidime, Piperacillin-Tazobactam, and Cefepime showed increased zone sizes over time, while Tobramycin’s zones steadily enlarged. Colistin consistently produced the largest zones at all time points.
Conclusion: The study highlights the significance of incubation time in disk diffusion testing for Pseudomonas aeruginosa. Adjusting incubation times can expedite results without incurring additional costs, enhancing the efficiency of antimicrobial susceptibility testing in clinical settings.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Wüllner D, Gesper M, Haupt A, Liang X, Zhou P, Dietze P, Narberhaus F, Bandow JE. Adaptive responses of Pseudomonas aeruginosa to treatment with antibiotics. Antimicrobial Agents and Chemotherapy. 2022 Jan 18; 66 (1):e00878-21. https://doi.org/10.1128/AAC.00878-21
.Al Yousef SA. In vitro bactericidal and imipenem synergistic effect of nano-silver against multiple drug-resistant Pseudomonas aeruginosa. Journal of King Saud University-Science. 2022 Jan 1; 34(1):101706. https://doi.org/10.1016/j.jksus.2021.101706
Webber DM, Wallace MA, Burnham CA. Stop Waiting for Tomorrow: Disk Diffusion Performed on Early Growth Is an Accurate Method for Antimicrobial Susceptibility Testing with Reduced Turnaround Time. Journal of clinical microbiology. 2022 May 18; 60(5):e03007-20
https://doi.org/10.1128/jcm.03007-20
Bitew, A. High prevalence of multi-drug resistance and extended spectrum beta lactamase production in non-fermenting gram-negative bacilli in Ethiopia. Infect. Dis. Res. Treat. 2019, 12. https://doi.org/10.1177/1178633719884951
Vaz S, Lall M. Potential public health impact of the development of antimicrobial resistance in clinical isolates of Pseudomonas aeruginosa on repeated exposure to biocides In vitro. Medical Journal of Dr. DY Patil University. 2021 Jan 1;14(1):45-50. http://doi.org/10.4103/mjdrdypu.mjdrdypu_353_20
Rehman, A.; Patrick, W.M.; Lamont, I.L. Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: New approaches to an old problem. J. Med. Microbiol. 2019, 68, 1–10. 8 https://doi.org/10.1099/jmm.0.000873
Holban, A.-M.; Chifiriuc, M.C.; Cotar, A.I.; Bleotu, C.; Grumezescu, A.M.; Banu, O.; Lazar, V. Virulence markers in Pseudomonas aeruginosa isolates from hospital acquired infections occurred in patients with underlying cardiovascular disease. Rom. Biotechnol. Lett. 2013, 18, 8843–8854: https://e-repository.org/rbl/vol.18/iss.6/13.pdf
Wang, C.; Ye, Q.; Jiang, A.; Zhang, J.; Shang, Y.; Li, F.; Zhou, B.; Xiang, X.; Gu, Q.; Pang, R.; et al. Pseudomonas aeruginosa Detection Using Conventional PCR and Quantitative Real-Time PCR Based on Species-Specific Novel Gene Target Identified by Pangenome Analysis. Front. Microbiol. 2022, 13, 820431. https://doi.org/10.3389/fmicb.2022.820431
Ahmed F, Mirani ZA, Mirani PN, Imdad MJ, Khan FZ, Khan MN, Khan AB, Li Y, Zhao Y. Pseudomonas aeruginosa Response to Acidic Stress and Imipenem Resistance. Applied Sciences. 2022 Aug 21; 12(16):8357. https://doi.org/10.3390/app12168357
Ikram S, Inam S, Shamim S, Haider SZ, Qureshi MA, Inam A. Emerging Patterns in
Antimicrobial Susceptibility Profiles of Pseudomonas SPP-Hospital Based Study. Pakistan Journal of Medical & Health Sciences. 2023 Mar 6; 17 (02):129.
https://doi.org/10.53350/pjmhs2023172129
Hamal D, Bhatt DR, Shrestha R, Supram HS, Nayak N, Gokhale S, Parajuli S. Changing trends in antibiotic susceptibility pattern among clinical isolates of Pseudomonas species in a tertiary care hospital in Nepal. Annals of Clinical Chemistry and Laboratory Medicine. 2021 Dec 31; 4(1):6-12. I: https://doi.org/10.3126/acclm.v4i1.42674
Memon SS, Haque S, Iqbal Z, Farooq L, Baloch FA, Lodhi M. In Vitro Activity Of Colistin And Other Agents Against Multidrug Resistant Pseudomonas Aeurginosa. Journal of Pharmaceutical Negative Results. 2023 Jan 1:870-6.
Mohamed A, Abdelhamid F. Antibiotic susceptibility of Pseudomonas aeruginosa isolated from different clinical sources. Zagazig Journal of Pharmaceutical Sciences. 2020 Feb 17; 28(2):10-7. 10.21608/ZJPS.2020.21777.1005
Lozano C, López M, Rojo-Bezares B, Sáenz Y. Antimicrobial susceptibility testing in Pseudomonas aeruginosa biofilms: one step closer to a standardized method. Antibiotics. 2020 Dec 9; 9(12):880. https://doi.org/10.3390/antibiotics9120880
Patients Milo Gatti , Bruno Viaggi , Gian Maria Rossolini , Federico Pea , and Pierluigi Viale. An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Antibiotics 2022, 11(1), 33; https://doi.org/10.3390/antibiotics11010033
Angela Raffaella Losito, Francesca Raffaelli, Paola Del Giacomo and Mario Tumbarell. New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: Antibiotics 2022, 11(5), 579; https://doi.org/10.3390/antibiotics11050579
S. Kanj , Matteo Bassetti, Pattarachai Kiratisin , Camilla Rodrigues , MaríaVirginia Villegas, Yunsong Yu , David van Duin.. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. International journal of antimicrobial agents. Volume 60, Issue 3, September 2022, 106633. https://doi.org/10.1016/j.ijantimicag. 2022.106633
Parmanik, A., Das, S., Kar, B. et al. Current Treatment Strategies Against Multidrug-Resistant Bacteria: A Review. Curr Microbiol 79, 388 (2022). https://doi.org/10.1007/s00284-022-03061-7
Ghazala Muteeb, Md Tabish Rehman, Moayad Shahwan and Mohammad Aatif. Origin of
Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review 2023, 16(11), 1615; https://doi.org/10.3390/ph16111615
Høiby N, Henneberg KÅ, Wang H, Stavnsbjerg C, Bjarnsholt T, Ciofu O, Johansen UR, Sams T. Formation of Pseudomonas aeruginosa inhibition zone during tobramycin disk diffusion is due to transition from planktonic to biofilm mode of growth. International journal of antimicrobial agents. 2019 May 1; 53(5):564-73. https://doi.org/10.1016/j.ijantimicag.2018.12.015